Scholarlink

<p>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy are standard first-line treatment for HR + /HER2– metastatic breast cancer (MBC). However, disease progression and treatment-limiting adverse events (AEs) remain major challenges, and the clinical benefit of CDK4/6i retreatment after prior exposure is uncertain. We retrospectively analyzed 78 patients with HR + /HER2 − MBC treated at two institutions (2018–2025) who received at least two CDK4/6i-containing therapies. Patients were classified according to treatment sequence: abemaciclib → abemaciclib (cohort 1), abemaciclib → palbociclib (cohort 2), or palbociclib → abemaciclib (cohort 3). Median time to treatment failure (TTF) of CDK4/6i retrial was 6, 10, and 6&#xa0;months across the three cohorts, respectively. Cohort 2 showed the most favorable retrial outcomes, with 64.5% of patients achieving a longer TTF on retrial than on initial CDK4/6i therapy. Discontinuation due to AEs was associated with a trend toward longer TTF compared with progression, whereas visceral metastasis was associated with shorter TTF in cohort 2 (hazard ratio 12.03, <i>p</i> = 0.01). CDK4/6i retrial may provide clinically meaningful benefit for selected patients, particularly with palbociclib after abemaciclib exposure or discontinuing initial therapy due to AEs, whole visceral metastasis predicts poorer outcomes with retreatment. These findings support individualized patient selection and warrant prospective validation to optimize sequencing strategies for CDK4/6is.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Muhan Yu,
  • Michiko Yamashita,
  • Mamoru Takada,
  • Daisuke Takabatake,
  • Mina Takahashi,
  • Mariko Kochi,
  • Maya Uno,
  • Midori Kondo,
  • Takeshi Nagashima,
  • Hiroshi Fujimoto,
  • Junta Sakakibara,
  • Ryotaro Teranaka,
  • Kenjiro Aogi,
  • Masayuki Otsuka

摘要

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy are standard first-line treatment for HR + /HER2– metastatic breast cancer (MBC). However, disease progression and treatment-limiting adverse events (AEs) remain major challenges, and the clinical benefit of CDK4/6i retreatment after prior exposure is uncertain. We retrospectively analyzed 78 patients with HR + /HER2 − MBC treated at two institutions (2018–2025) who received at least two CDK4/6i-containing therapies. Patients were classified according to treatment sequence: abemaciclib → abemaciclib (cohort 1), abemaciclib → palbociclib (cohort 2), or palbociclib → abemaciclib (cohort 3). Median time to treatment failure (TTF) of CDK4/6i retrial was 6, 10, and 6 months across the three cohorts, respectively. Cohort 2 showed the most favorable retrial outcomes, with 64.5% of patients achieving a longer TTF on retrial than on initial CDK4/6i therapy. Discontinuation due to AEs was associated with a trend toward longer TTF compared with progression, whereas visceral metastasis was associated with shorter TTF in cohort 2 (hazard ratio 12.03, p = 0.01). CDK4/6i retrial may provide clinically meaningful benefit for selected patients, particularly with palbociclib after abemaciclib exposure or discontinuing initial therapy due to AEs, whole visceral metastasis predicts poorer outcomes with retreatment. These findings support individualized patient selection and warrant prospective validation to optimize sequencing strategies for CDK4/6is.